Work

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

Year: 2014

Type: article

Abstract: Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

Source: OncoImmunology

DOI: 10.4161/21624011.2014.962401

Authors: Eric R Lutz, Heather Kinkead, Elizabeth M Jaffee, Lei Zheng

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913